Asia Pacific Blood Glucose Monitoring Market Size was valued at USD 1.1 Billion in 2022. The Asia Pacific Blood Glucose Monitoring market industry is projected to grow from USD 1.25 Billion in 2023 to USD 3.46 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.60% during the forecast period (2023 - 2032). Growing spread of diabetes and rise in demand of consistent glucose monitoring equipment are the key market drivers enhancing the market’s expansion.
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
The growing spread of diabetes across the region is driving Market CAGR for Asia Pacific Blood Glucose Monitoring. The majority of diabetics live in Asia-Pacific nations like China and India, where the prevalence rate is on average around 8.5%. Devices that measure blood glucose are used to diagnose and treat diabetes effectively. The market is driven by an increase in the number of diabetics using blood glucose monitoring equipment. Obesity is regarded as one of the primary causes of the disease state, particularly type 2 diabetes. Additionally, other elements like technical advancements and inventions make it easier to measure blood glucose levels. The market for glucose monitoring is typically driven by the early detection of hypo- and hyperglycemic situations, which are assisted by these devices.
Additionally, rising diabetes incidence is causing a surge in the diabetic population, which is fueling market expansion. Around 88 million persons in the South East Asia area had diabetes as of November 2019, according to the International Diabetes Federation (IDF). By 2045, this population was predicted to grow to 153 million. Therefore, it is anticipated that the growing number of diabetics will increase demand for continuous glucose monitors and therefore propel market expansion.
In the upcoming years, there may be further prospects for the expansion of the Asia-Pacific glucose monitoring devices market due to the level of precision of the medicine, test results, and counseling. The rapid technical advancement in glucose monitoring devices, however, may shortly provide further challenges to the market's expansion in the Asia-Pacific region.
The rise in awareness of diabetes self-management is among the key factors anticipated to propel the growth of the Asia-Pacific glucose monitoring devices market during the forecast period. The market for glucose monitoring devices in Asia-Pacific is also predicted to increase as a result of the swiftly changing regulatory regulations and advantageous investment policies. On the other side, the expansion of the Asia-Pacific glucose monitoring devices market in the timeline period is further expected to be hampered by the strict regulation of glucose monitoring devices by regulatory organizations. Thus, driving the Asia Pacific Blood Glucose Monitoring market revenue.
The Asia Pacific Blood Glucose Monitoring market segmentation, based on the product type, is divided into Invasive glucose monitoring, Flash Glucose Monitoring, and CGM. The CGM category dominated the market. Fingersticks, a glucose meter, or a continuous glucose monitoring (CGM) device can all be used to test glucose if they are accessible. The usage of CGM devices is expanding, particularly among those who administer numerous daily insulin injections or use an insulin pump.
Based on the application of Asia Pacific Blood Glucose Monitoring, the Asia Pacific Blood Glucose Monitoring market segmentation includes Type 1 diabetes and Type 2 diabetes. The category with the biggest share and the quickest projected CAGR during the projection period is type 2 diabetes. The high incidence rate is what accounts for the huge income share. Changes in lifestyle, bad eating patterns, sedentary behavior, and excessive body weight are some of the main causes of disease. Therefore, the need for blood glucose level monitoring to ensure that these patients' treatment plans are optimized drives market revenue. Additionally, a higher incidence rate in developed nations combined with increased awareness of SMBG among people with type 2 diabetes may boost market revenue.
The Asia Pacific Blood Glucose Monitoring market segmentation, based on end-user, includes Diagnostics centers, Hospitals, and Clinics. During the projection period, the sector for hospitals is anticipated to increase at the greatest CAGR. because of long-term predicted increases in hospital healthcare expenditures and infrastructure development. Additionally, BGM devices are being used more frequently in outpatient and inpatient hospital settings since they improve patients' quality of life while providing practitioners with precise data in a matter of seconds. For the transport and storage of patient data, hospitals have extra systems in place.
Figure 1 Asia Pacific Blood Glucose Monitoring Market, by End-User, 2022 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
By region, the study provides market insights into Asia-Pacific. During the projected period, the China Blood Glucose Monitoring market is expected to dominate over the course of the forecasted period. A sizable share of the nation's patient population has fueled market demand. The ability to spend more money on disease control and treatment has fueled industry expansion. The market will rise as a result of increased product accessibility, more consumer awareness, and business expansion by industry participants across the nation. Additionally, as older people are more prone to develop type 2 diabetes, the nation's aging population is anticipated to enhance industry demand. Additionally, government programs and campaigns to raise awareness of diabetes management will spur business growth.
Figure 2 Â ASIA PACIFIC BLOOD GLUCOSE MONITORING MARKET SHARE BY REGION 2022 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
India’s Blood Glucose Monitoring market accounts for the fastest market share. Since there is financing available for research and because the government supports research and development. This is anticipated to keep driving the Indian market for the anticipated period. Furthermore, countries like Japan, Australia, and the Republic of Korea are experiencing rapid growth in the blood glucose monitoring market. India's blood glucose monitoring market is expanding at the quickest rate due to the country's big patient population, high healthcare spending, and rapidly changing medical technology. Additionally, it is anticipated that increasing demand for novel treatment methods in countries like South Korea and India will fuel the fastest-growing industry. Rising healthcare expenditures are also anticipated to increase demand for more advanced technologies, which might expand the market for blood glucose monitoring devices
Asia Pacific Blood Glucose Monitoring Key Market Players & Competitive Insights
Leading market players are investing capital and resources across research and development to extend their product offerings, this is expected to help the Asia Pacific Blood Glucose Monitoring market, grow even more. Market leaders and manufacturers are also adopting various strategies to expand their worldwide footprint, with important market developments including new product developments & launches, contracts & agreements, mergers & acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Asia Pacific Blood Glucose Monitoring industry must offer cost-effective items.
The manufacturers are making use of locally available resources to minimize the production costs which will aid the growth of the Asia Pacific Blood Glucose Monitoring industry to benefit clients and increase the market sector. In recent years, the Asia Pacific Blood Glucose Monitoring industry has offered some of the most significant advantages to medicine. Major players in the Asia Pacific Blood Glucose Monitoring Market, including Abbott Laboratories, Arkay Inc., Bayer Healthcare AG, F. Hoffmann-La Roche, Goldsite Diagnostics Inc., GlySure Ltd., Sphere Medical, Dexcom, LifeScan, and others, are attempting to increase market demand by investing in research and development operations.
Continuous glucose monitoring (CGM) systems are created, developed, and sold by Dexcom Inc. (Dexcom) for use by patients with diabetes and medical professionals in hospitals. Integrated Dexcom G6 CGM system, Dexcom Share remote monitoring system, Dexcom Real-Time API, Dexcom ONE CGM system, related software, and mobile apps are some of the company's main products. It also offers various support services including Dexcom Care training to CGM system customers. Endocrinologists, physicians, diabetes educators, and others can purchase products from the business. In addition to using a network of distributors in Australia, the US, New Zealand, and other nations in Asia, Europe, Africa, Latin America, and the Middle East, it distributes items directly in the US, Austria, Canada, Germany, Switzerland, and the UK. In the US, San Diego, California, is home to the Dexcom headquarters. In July 2023, A Type 2 diabetes monitor with a 15-day sensor and a cash-pay option for patients who are not covered by Medicare and health insurers but want daily decision support is being developed by Dexcom, a manufacturer of continuous glucose monitors.
A wide variety of healthcare goods are discovered, developed, produced, and sold by Abbott Laboratories (Abbott), including branded generic medications, diagnostic tools and procedures, and infant, child, and adult nutritional supplements. The business also sells a range of medical devices, such as those for neuromodulation, electrophysiology, rhythm control, vascular and structural cardiac devices, and heart failure. The business also sells dietary supplements, minerals, and nutrition goods. It runs manufacturing sites all around the world and has research and development centers in the US, China, Colombia, India, Singapore, Spain, and the UK. The corporation sells its goods across Africa, the Middle East, Latin America, North America, and the Asia-Pacific region. In June 2022, Abbott disclosed that it is developing a cutting-edge wearable with a sensor for continuous glucose and ketone monitoring. The system has been given the breakthrough device classification by the U.S. Food and Drug Administration, which is meant to expedite the review of cutting-edge technology that potentially improve the lives of patients with fatal or permanently debilitating diseases or conditions.
Key Companies in the Asia Pacific Blood Glucose Monitoring market include
Asia Pacific Blood Glucose Monitoring Industry Developments
February 2023Â In addition to announcing the availability of its Dexcom G6 CGM System in Singapore for diabetics two years of age and older, including pregnant women, Dexcom, Inc. also announced the choice of DKSH Singapore Pte Ltd as a provider of sales, marketing, and distribution services.
December 2022Â According to a Terumo Company release, the Dexcom G6 CGM System now has expanded payment coverage under the Japanese medical insurance system. Dexcom G6 CGM System users in Japan will be able to obtain reimbursement on a greater scale thanks to the recently established "C150" category.
Rest of Asia-Pacific
Asia Pacific Blood Glucose Monitoring Report Scope| Report Attribute/Metric | Details |
| Market Size 2022 | USD 1.1 Billion |
| Market Size 2023 | USD 1.25 Billion |
| Market Size 2032 | USD 3.46 Billion |
| Compound Annual Growth Rate (CAGR) | 13.60% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Application, End-User, and Region |
| Geographies Covered | Asia Pacific |
| Countries Covered | China, Japan, India, Australia, South Korea |
| Key Companies Profiled | Abbott Laboratories, Arkay Inc., Bayer Healthcare AG, F. Hoffmann-La Roche, Goldsite Diagnostics Inc., GlySure Ltd., Sphere Medical |
| Key Market Opportunities | Growing prevalence of diabetes |
| Key Market Dynamics | Increase in concerns about health and fitness |
Asia Pacific Blood Glucose Monitoring Market Highlights:
Frequently Asked Questions (FAQ) :
The Asia Pacific Blood Glucose Monitoring market size was valued at USD 1.1 Billion in 2022.
The market is projected to grow at a CAGR of 13.60% during the forecast period, 2023-2032.
China had the largest share of the market
The key players in the market are Abbott Laboratories, Arkay Inc., Bayer Healthcare AG, F. Hoffmann-La Roche, Goldsite Diagnostics Inc., GlySure Ltd., and Sphere Medical.
The CGM category dominated the market in 2022.
Type 2 diabetes had the largest share of the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
